Government-Owned Inventions; Availability for Licensing, 9520 [2021-03045]
Download as PDF
<![CDATA[
9520
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
2. Effective Time Period, Section XII,
Add to the End of the Section:
Liability protections for Qualified
Persons under sections V(f) and V(d) of
the declaration begin on February 8,
2021 and last through October 1, 2024.
Authority: 42 U.S.C. 247d–6d.
Norris Cochran,
Acting Secretary, Department of Health and
Human Services.
[FR Doc. 2021–03106 Filed 2–11–21; 4:15 pm]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Epstein-Barr Virus Antibody That
Blocks Fusion And Neutralizes Virus
Infection of B Cells
Description of Technology
Epstein-Barr virus (EBV) is the most
common cause of infectious
mononucleosis and is associated with
nearly 200,000 cancers and 140,000
deaths each year. EBV-associated
cancers include Hodgkin’s lymphoma,
non-Hodgkin’s lymphoma, Burkitt B cell
lymphoma, and EBV post-transplant
lymphoproliferative disease. The latent
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
reservoir for EBV in the body is the B
lymphocyte. Thus, blocking B cell
infection is important for reducing EBVrelated disease.
EBV can infect both B cells and
epithelial cells; however, the method of
entry differs between these two cell
types. To initiate B cell infection, EBV
glycoprotein 350 (gp350) binds to
compliment receptor 2 (CR2; also
known as CD21), followed by binding of
glycoprotein 42 (gp42) to HLA class II
molecules, which triggers fusion of EBV
with the B cell, allowing virus entry into
the cell. Fusion also requires the EBV
proteins gH/gL, which are found
complexed with gp42 as a heterotrimer,
and gB. Infection of epithelial cells is
initiated by the binding of the EBV
protein BMRF2 to cellular integrins,
followed by binding of gH/gL to ephrin
receptor A2 and integrins, which
triggers fusion by EBV gB.
Monoclonal antibodies that
specifically bind EBV gp42 are
described by this invention. The gp42specific antibodies are capable of
neutralizing EBV infection and
inhibiting fusion of EBV with B cells.
The monoclonal antibodies can be used
for the treatment or prophylaxis of EBV
infection, prevention of EBV-associated
disease or infection in
immunocompromised subjects,
diagnosis of EBV infection, and
detection of EBV in a biological sample.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
•
•
•
•
Viral diagnostics
Viral therapeutics
Viral prophylaxis
Vaccine research
Competitive Advantages
• Ease of manufacture
• Strongly neutralizing antibodies
• Alternative to EBV vaccines
Development Stage
• In vivo data assessment (animal)
Inventors: Jeffrey Cohen (NIAID), Wei
Bu (NIAID), Nathan Board (NIAID),
Kennichi Dowdell (NIAID).
Intellectual Property: HHS Reference
No. E–020–2020–0—U.S. Provisional
Application No. 62/979,070, filed
February 20, 2020.
Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
interested in collaborative research to
further develop, evaluate, or
commercialize for development of a
vaccine for respiratory or other
infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.
Dated: January 28, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–03045 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Renal RC2
Applications.
Date: March 19, 2021.
Time: 3:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ryan G. Morris, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, 6707
Democracy Boulevard, Room 7015, Bethesda,
MD 20892–2542, 301–594–4721,
ryan.morris@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 86, Number 29 (Tuesday, February 16, 2021)]
[Notices]
[Page 9520]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03045]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Soukas, J.D., 301-594-8730;
[email protected]. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus
Infection of B Cells
Description of Technology
Epstein-Barr virus (EBV) is the most common cause of infectious
mononucleosis and is associated with nearly 200,000 cancers and 140,000
deaths each year. EBV-associated cancers include Hodgkin's lymphoma,
non-Hodgkin's lymphoma, Burkitt B cell lymphoma, and EBV post-
transplant lymphoproliferative disease. The latent reservoir for EBV in
the body is the B lymphocyte. Thus, blocking B cell infection is
important for reducing EBV-related disease.
EBV can infect both B cells and epithelial cells; however, the
method of entry differs between these two cell types. To initiate B
cell infection, EBV glycoprotein 350 (gp350) binds to compliment
receptor 2 (CR2; also known as CD21), followed by binding of
glycoprotein 42 (gp42) to HLA class II molecules, which triggers fusion
of EBV with the B cell, allowing virus entry into the cell. Fusion also
requires the EBV proteins gH/gL, which are found complexed with gp42 as
a heterotrimer, and gB. Infection of epithelial cells is initiated by
the binding of the EBV protein BMRF2 to cellular integrins, followed by
binding of gH/gL to ephrin receptor A2 and integrins, which triggers
fusion by EBV gB.
Monoclonal antibodies that specifically bind EBV gp42 are described
by this invention. The gp42-specific antibodies are capable of
neutralizing EBV infection and inhibiting fusion of EBV with B cells.
The monoclonal antibodies can be used for the treatment or prophylaxis
of EBV infection, prevention of EBV-associated disease or infection in
immunocompromised subjects, diagnosis of EBV infection, and detection
of EBV in a biological sample.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Viral diagnostics
Viral therapeutics
Viral prophylaxis
Vaccine research
Competitive Advantages
Ease of manufacture
Strongly neutralizing antibodies
Alternative to EBV vaccines
Development Stage
In vivo data assessment (animal)
Inventors: Jeffrey Cohen (NIAID), Wei Bu (NIAID), Nathan Board
(NIAID), Kennichi Dowdell (NIAID).
Intellectual Property: HHS Reference No. E-020-2020-0--U.S.
Provisional Application No. 62/979,070, filed February 20, 2020.
Licensing Contact: Peter Soukas, J.D., 301-594-8730;
[email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize for development of a vaccine for
respiratory or other infections. For collaboration opportunities,
please contact Peter Soukas, J.D., 301-594-8730; [email protected].
Dated: January 28, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-03045 Filed 2-12-21; 8:45 am]
BILLING CODE 4140-01-P
